Efinopegdutide
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Trial Timeline
Jul 29, 2024 → Jun 27, 2025
NCT ID
NCT06482112About Efinopegdutide
Efinopegdutide is a phase 2 stage product being developed by Merck for Metabolic Dysfunction-Associated Steatotic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06482112. Target conditions include Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06482112 | Phase 2 | Completed |
| NCT06052566 | Phase 1 | Completed |
Competing Products
20 competing products in Metabolic Dysfunction-Associated Steatotic Liver Disease